Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions (clinicaltrials.gov) - Oct 23, 2026 - P4 | N=20 | Not yet recruiting | Sponsor: Ruijin Hospital
New P4 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
|